^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    CDK4 inhibitor

    Related drugs:
    5d
    postMONARCH: Abemaciclib (LY2835219) Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer (clinicaltrials.gov)
    P3, N=368, Active, not recruiting, Eli Lilly and Company | Trial completion date: Feb 2026 --> Dec 2027
    Trial completion date
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    Verzenio (abemaciclib) • fulvestrant
    7d
    Abemaciclib in Treating Patients With Advanced, Refractory, and Unresectable Digestive System Neuroendocrine Tumors (clinicaltrials.gov)
    P2, N=20, Active, not recruiting, University of Washington | Trial completion date: Sep 2027 --> Jul 2026 | Trial primary completion date: Sep 2026 --> Nov 2025
    Trial completion date • Trial primary completion date
    |
    Verzenio (abemaciclib)
    7d
    Safety and Efficacy of SPH4336 in Combination With Endocrine Therapy in the Treatment of Locally Advanced or Metastatic Breast Cancer (clinicaltrials.gov)
    P2/3, N=254, Recruiting, Shanghai Pharmaceuticals Holding Co., Ltd | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    fulvestrant • SPH4336
    8d
    SIE-3: A Study to Investigate the Efficacy and Safety of Letrozole SIE Compared With Femara® (Both Combined With the CDK4/6 Inhibitor Palbociclib) in Postmenopausal Women With HR-Positive, HER2-Negative, Advanced Breast Cancer (clinicaltrials.gov)
    P3, N=300, Not yet recruiting, Rovi Pharmaceuticals Laboratories
    New P3 trial
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative
    |
    Ibrance (palbociclib) • letrozole
    9d
    CAPItana: A Phase IIIB Study to Evaluate the Use of Capivasertib in Combination With Fulvestrant in Patients With Advanced Breast Cancer Who Have Relapsed/Progressed on ET and CDK4/6 Inhibitor Reflecting Real World Clinical Practice in Spain (clinicaltrials.gov)
    P3, N=101, Active, not recruiting, AstraZeneca | Recruiting --> Active, not recruiting
    Enrollment closed • Real-world evidence
    |
    HER-2 (Human epidermal growth factor receptor 2) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • PTEN (Phosphatase and tensin homolog) • AKT1 (V-akt murine thymoma viral oncogene homolog 1) • CDK4 (Cyclin-dependent kinase 4)
    |
    HER-2 negative
    |
    fulvestrant • Truqap (capivasertib)
    9d
    A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-0587 as a Monotherapy and in Combination With Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (clinicaltrials.gov)
    P1, N=136, Recruiting, Genentech, Inc. | Not yet recruiting --> Recruiting
    Enrollment open • First-in-human
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    giredestrant (RG6171) • omeprazole
    15d
    BREAKER: Breast Cancer RElapsed in Patients Treated With Adjuvant CDK4/6 Inhibitors: (clinicaltrials.gov)
    P=N/A, N=750, Recruiting, European Institute of Oncology | Not yet recruiting --> Recruiting
    Enrollment open • Real-world evidence
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    19d
    Ribociclib and Bicalutamide in AR+ TNBC (clinicaltrials.gov)
    P1/2, N=37, Active, not recruiting, Kari Wisinski | Recruiting --> Active, not recruiting | Trial completion date: Sep 2025 --> Oct 2026 | Trial primary completion date: Sep 2025 --> Oct 2026
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • AR (Androgen receptor)
    |
    HER-2 negative • AR positive • HER-2 negative + ER positive
    |
    Kisqali (ribociclib) • bicalutamide
    21d
    Efficacy and Safety of Trastuzumab Rezetecan Followed by CDK4/6 Inhibitors and Endocrine Therapy in HR+/HER2-Low/Ultra-Low Advanced Breast Cancer (clinicaltrials.gov)
    P2, N=45, Recruiting, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Herceptin (trastuzumab) • fulvestrant • trastuzumab rezetecan (SHR-A1811)
    29d
    SIGNAL-ER 101: Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer (clinicaltrials.gov)
    P=N/A, N=725, Not yet recruiting, Natera, Inc. | Phase classification: P2 --> P=N/A | Initiation date: Nov 2025 --> Mar 2026
    Phase classification • Trial initiation date
    |
    Signatera™
    1m
    LEADER: CDK 4/6 Inhibitor, Ribociclib, With Adjuvant Endocrine Therapy for ER-positive Breast Cancer (clinicaltrials.gov)
    P2, N=120, Active, not recruiting, Massachusetts General Hospital | Trial primary completion date: Oct 2025 --> Apr 2026
    Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor)
    |
    HER-2 negative
    |
    Kisqali (ribociclib)
    1m
    A Study of BG-75098 Alone and in Combination With Other Agents in Adults With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=105, Recruiting, BeOne Medicines | Not yet recruiting --> Recruiting
    Enrollment open
    |
    fulvestrant